Replies to post #181483 on Biotech Values

[jq1234]

TTPH: eravacycline IV/oral switch for complicated urinary tract infection (cUTI) ph3 IGNITE2 lead-in portion result is coming in Sept.

Mr. Macdonald added: "We're looking forward to a number of important milestones over the next several quarters. In September 2014, we expect to report top-line results from the lead-in portion of IGNITE 2, which will be the first data on the IV-to-oral switch of eravacycline in cUTI patients and, we expect, will inform the selection of the oral dose to be taken forward into the pivotal portion of IGNITE 2. We also remain on track with our goals of reporting top-line results from IGNITE 1 in early first quarter 2015 and top-line results from the pivotal portion of IGNITE 2 in mid-2015, and our goal of filing for regulatory approval of eravacycline in the U.S. by the end of 2015."

http://ir.tphase.com/releasedetail.cfm?ReleaseID=865902